

03 #S CASE D0020 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Stephen C. D'Amico

Type or print name

Short in

December 12, 2001

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

FEDER ET AL.

APPLICATION NO: 09/932,145

FILED: 08/17/01

FOR: NOVEL IMIDAZOLINE RECEPTOR HOMOLOGS

Assistant Commissioner for Patents

Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants-believe-this-paper-is-being-filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-5289

Date: December 12, 2001

Agent for Applicants Reg. No. 46,652

Stephen C. D'Amico

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION



ATTY. DOCKET NO. D0020 NP APPLICATION NO. 09/932,145 APPLICANT FEDER ET AL. FILING DATE 08/17/01

Group

U.S. PATENT DOCUMENTS

			0.0	EITT DOODMEITTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
_	AA						
	AB				*		
	AC						-
	AD						
	AE						
	AF						· · · · · · · · · · · · · · · · · · ·
	AG						·
	АН						* **
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
	AM	W09906548	2/11/99	PCT				
9*	AN	W099/63088	12/9/99	PCT				
	AO	W001/57270	8/9/01	PCT				
	AP							
	AQ							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

•	AR	Escriba, Pablo V. et al. (1995) Molecular Brain Research; Vol 32;pp 187-196
	AS	Farsang C. et al., (1999) Brain Research Bulletin, Vol. 49, No. 5 pp. 317-331
	AT	Chan, Susan L. F. et al., (1993) European Journal of Pharmacology; Vol. 230 pp. 375-378

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURFECTATION

(Use several sheets if necessary)

JAN 0 4 2002

ATTY. DOCKET NO. D0020 NP APPLICATION NO. 09/932,145 APPLICANT FEDER ET AL. FILING DATE 08/17/01

Group

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent pages, Etc.)

	_	OTHER DOSOWIEN 15 (Including Author, Title, Date, Pertinent pages, Etc.)		
1	AA	Chan, Susan L. F., et al. (1994) British Journal of Pharmocology, Vol. 112; pp 1065-1070		
	АВ	Altschul, Stephen F., et al. (1997) Nucleic Acids Research, Vol. 25, No. 17; pp 3389-3402		
•	AC	Garcia-Sevilla, Jesus A., et al. (1999) NY Acad. Science, June 21; pp 392-403		
•	AD	NCBI Entrez, Genbank Accession No. CAA37509 [gi:9115] Swimmer, C., et al., April 7, 1992		
0	AE	NCBI Entrez, Genbank Accession No. BAB67791.KIAA1898 [gi:15620855], Nagase, T. et al. September 15, 2001		
	AF	NCBI Entrez, Genbank Accession No. AAH14114 [gi:15559497], Strausberg, R., Sept. 12, 2001		
\$	AG	Incyte EST, Clone Sequence ID: 2499870		
	АН			
	_AI			
	AJ			
	AK			
	AL			
	АМ			
	AN			
EXAMINER		DATE CONSIDERED		

DATE CONSIDERED

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.